





FIGURE 1



FIGURES 2A - 2B




FIGURE 3

Group #	N	Agent	Dose level (mg/kg)	Volume	Route of Admin.	Dosing Schedule	Terminal bleed (for serum) times	Tissue harvest
1	15	Vehicle (PBS)	N/A	0.2 ml	IV	qd x 1	3 mice/group: • 15 min. • 30 min. • 1 hr. • 4 hr. • 12 hr.	Harvest liver, kidney, lung, and spleen; snap freeze and store at -80°C
2	15	Anti-PBP1 PNA-peptide	1	0.2 ml	IV	qd x 1		
3	15	Anti-PBP1 PNA-peptide	3.3	0.2 ml	IV	qd x 1		
4	15	Anti-PBP1 PNA-peptide	10	0.2 ml	IV	qd x 1		

Terminally bleed 3 mice/group/time point at 15 min, 30 min, 1 hr, 4 hr, and 12 hr.

FIGURE 4

Group #	N	Agent	Dose level (mg/kg)	Volume	Route of Admin.	Dosing Schedule
1	10	Vehicle (PBS)	N/A	0.2 ml	IV	qd x 7
2	10	Anti-PBP1 PNA-peptide	10	0.2 ml	IV	qd x 7
3	10	Anti-PBP1 PNA-peptide	10	0.2 ml	IV	q2d x 4
4	10	Anti-PBP1 PNA-peptide	10	0.2 ml	IV	q3d x 3

FIGURE 5

6/8




FIGURE 6

Development of Blood Infection Mouse Model




FIGURE 7

Group #	N	MRSA			Treatment			
		Dose (2×10^7 CFU/mL)	Volume (mL)	Route	Agent	Dose (mg/kg)	Volume (mL)	Route
1	10	4×10^6	0.2	IV	Vehicle (PBS)	10	0.2	IV
2	10	4×10^6	0.2	IV	Anti-PBP1 PNA-peptide	10	0.2	IV
3	10	4×10^6	0.2	IV	Vancomycin	2	0.2	IV
								Dose Schedule
								b.i.d. X 4
								b.i.d. X 4
								b.i.d. X 4




FIGURE 8